<DOC>
	<DOCNO>NCT01637272</DOCNO>
	<brief_summary>multi-center , phase II study evaluate efficacy , safety pharmacokinetics pasireotide patient dump syndrome</brief_summary>
	<brief_title>Intra-patient Dose Escalation Study Evaluating Efficacy , Safety Pharmacokinetics Pasireotide ( SOM230 ) Subcutaneous ( s.c. ) Followed Pasireotide LAR Patients With Dumping Syndrome</brief_title>
	<detailed_description>43 adult patient dump syndrome receive 3 month pasireotide s.c. dose escalation phase ( dose increase base presence hypoglycemia OGTT ) . From Month 3- Month 6 patient switch pasireotide LAR . The core phase study complete tghe end Month 6 . Patients offer enter 6 month extension phase experience benefit pasireotide LAR treatment</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Dumping Syndrome</mesh_term>
	<criteria>Inclusion criterion : . 1 . Male female patient ≥ 18 year age 2 . Postgastric esophageal bypass surgery , match one criterion : Bariatric surgery : 6 month sign informed consent Esophageal cancer surgery : must disease free study entry Gastric cancer surgery : must stage 0 I must disease free study entry 3 . Patient document diagnosis Dumping Syndrome define : History of/or active symptom associate dump syndrome ( e.g . postprandial tachycardia , bloating , diarrhea ) Documented history hypoglycemia base either : 1. glucose &lt; 50mg/dL sporadic schedule blood analysis 2. glucose value &lt; 60 mg/dL ≤ 3.3 mmol/L 90,120 , 150 180 min OGTT 4 . Patients must least one glucose level &lt; 60 mg/dL ( ≤ 3.3 mmol/L ) 90 , 120 , 150 180 min 3hour OGTT screen 5 . Patients esophageal cancer must negative CT MRI scan ( neck , thoracic , upper abdominal ) albumin ≥3.5g/dl baseline 6 . Patients gastric cancer must negative CT MRI scan ( total abdomen ) 7 . Karnofsky Performance Status ≥ 60 ( i.e . require occasional assistance , able care personal need ) 8 . Patients receive therapy dump syndrome ( acarbose , gama guar , pectin ) must stop treatment allow wash period prior sign inform consent ( i.e . least 2 week last previous therapy first dose study medication study ) . 9 . Patients able provide provide signed write informed consent prior study participation . Exclusion criterion : 1 . Bariatric patient lap band . 2 . Patients diagnosis Diabetes Mellitus . 3 . Patients fail treatment somatostatin analogue dump syndrome past 4 . Patients treat somatostatin analogue past , must appropriate interval last administration somatostatin analogue treatment study drug follow Octreotide s.c. ≥ 72 hour Octreotide LAR ≥ 56 day ( 8 week ) Lanreotide Autogel ≥ 98 day ( 14 week ) Lanreotide SR ≥ 28 day ( 4 week ) Patients already treat pasireotide 5 . Patients know hypersensitivity somatostatin analogue . 6 . Patients receive anticancer therapy ( chemotherapy and/or radiotherapy ) 7 . Patients severe and/or uncontrolled medical condition condition could affect participation study : Patients presence active suspect acute chronic uncontrolled infection history immunodeficiency , include positive HIV test result ( ELISA Western blot ) . An HIV test require ; however , previous medical history review . Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study treatment . Lifethreatening autoimmune ischemic disorder . Patients presence active suspect acute chronic uncontrolled infection 8 . Inadequate end organ function define : Inadequate bone marrow function : WBC &lt; 2.5 x 109/L Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Hb &lt; 9 g/dL INR ≥ 1.3 Serum creatinine &gt; 2.0 mg/dL Alkaline phosphatase &gt; 2.5 x ULN Serum total bilirubin &gt; 1.5 x ULN ALT AST &gt; 2 x ULN 9 . History liver disease , cirrhosis chronic active hepatitis B C. 10 . Presence Hepatitis B surface antigen ( HbsAg ) and/ orPresence Hepatitis C antibody test ( antiHCV ) 11 . History , current alcohol and/or drug misuse/abuse within past 12 month 12 . Patients symptomatic cholelithiasis 13 . Patients abnormal coagulation ( PT PTT elevate 30 % normal limit ) . 14 . Patients continuous anticoagulation therapy . Patients anticoagulant therapy must complete washout period least 10 day confirm normal coagulation parameter study inclusion ( patient receive aspirin day allow enrol ) . 15 . Patients hypothyroid adequate replacement therapy 16 . Patients undergone major surgery/surgical therapy cause within 1 month . Patients recover surgery good clinical condition enter study . 17 . Patients history primary malignancy ( `` another '' primary malignancy patient gastric esophageal cancer ) within last 1 year , exception locally excise nonmelanoma skin cancer , carcinoma situ uterine cervix , excise mucosal gastric cancer mucosal colon cancer . 18 . Patients history noncompliance medical regimen consider potentially unreliable unable complete entire study . 19 . Clinically significant abnormal laboratory value consider investigator medical monitor sponsor clinically significant could affect interpretation study result . 20 . QTrelated exclusion criterion : QTcF screen &gt; 470 msec History syncope family history idiopathic sudden death Sustained clinically significant cardiac arrhythmia Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade AV block Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes , Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism cardiac failure Family history long QT syndrome Concomitant medication know prolong QT interval . Potassium &lt; = 3.5 mEq/L Magnesium &lt; 0.7 mEq/L 21 . Participation clinical investigation within 4 week prior dose longer required local regulation . ( Use investigational drug within 1 month prior dose ) 22 . Significant acute illness within two week prior dose . 23 . Female patient pregnant lactating , childbearing potential ( defined woman physiologically capable become pregnant ) practice effective method contraception/birth control . Sexually active male must use condom intercourse take drug 2 month last dose study drug father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . Effective contraception method include : Use oral , injected implant hormonal method contraception Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/ vaginal suppository Total abstinence patient sterilization ( male female )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Dumping syndrome</keyword>
</DOC>